• Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population. (cellsurgicalnetwork.com)
  • To evaluate clinical outcomes of autologous peripheral blood stem cell transplantation (APBCST) between opticospinal multiple sclerosis (OSMS) and conventional multiple sclerosis (CMS) during disease progressive stage in a Chinese population. (cellsurgicalnetwork.com)
  • I have expertise in novel therapies for acute myeloid leukemia, stem cell mobilization and homing, as well as stem cell transplantation. (rochester.edu)
  • In order to assess the incidence and analyze reasons which cause prolongation of hospital stay in patients engrafted after peripheral blood stem cell transplantation (PBSCT), we performed this retrospective analysis. (nature.com)
  • Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. (nature.com)
  • Detection of Mucor velutinosus in a blood culture after autologous peripheral blood stem cell transplantation: a pediatric case report. (wikipedia.org)
  • Stem cell transplantation is performed after high-dose chemotherapy (HDC) to restore a cancer patient's blood and immune cell production capacity. (bdbiosciences.com)
  • 30,000 patients with blood-related malignancies receive HDC, which, if the response is satisfactory, could subsequently be followed by hematopoietic stem cell transplantation (HSCT). (bdbiosciences.com)
  • 1 Improvements in transplantation techniques, including the wider use of cell selection, have contributed to a significant reduction in the morbidity and mortality associated with conventional transplantation. (bdbiosciences.com)
  • This pharmacologically induced egress of HSCs into peripheral blood, called mobilization, is utilized as the preferred strategy for generating HSCs for transplantation. (bdbiosciences.com)
  • 3 Autologous stem cell transplantation almost exclusively uses peripheral blood, while for allogeneic SCT, T-lymphocytes in the peripheral blood could pose some danger. (bdbiosciences.com)
  • The number of viable CD45+/CD34+ cells will determine the quality of the harvested specimen for transplantation. (bdbiosciences.com)
  • An accurate measurement of CD34 is critical for dose requirement protocols in stem cell transplantation. (bdbiosciences.com)
  • To date, six patients have relapsed and died, two after a second hematopoietic stem cell transplantation without T-cell depletion or administration of unmodified T-cells. (frontiersin.org)
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is applied successfully to the treatment of many hematopoietic malignancies, but remains limited by severe acute graft-versus-host-disease (aGvHD). (frontiersin.org)
  • Therefore, a central goal in clinical care of SDS patients is to identify incipient leukemic transformation and initiate pre-emptive treatment with allogeneic stem cell transplantation. (nature.com)
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
  • High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. (smw.ch)
  • The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
  • Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. (smw.ch)
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
  • Journal of Stem Cell Research and Transplantation is an international, open access, peer reviewed, scholarly journal committed to publish articles in diversified fields of transplantations and applications of stem cell research. (slideshare.net)
  • The aim of the academic journal is to provide a platform for researchers, scientists, physicians, and other health professionals to find latest research information in the areas of stem cell research, transplantations such as stem cell transplantation, transplantation immunology, kidney transplantation and its treatment. (slideshare.net)
  • The Journal of Stem Cell Research and Transplantation publishes latest scientific information, and is generously accessible across the world through internet to go halves the innovations of the researchers for intellectual advancement in this field. (slideshare.net)
  • 184 had no cardiac events after stem cell transplantation. (slideshare.net)
  • Discussion Stem cell transplantation is well and truly underway in South East Asia. (slideshare.net)
  • Peripheral blood stem cell mobilization is very important in hematopoietic stem cell transplantation (as a recent alternative to transplantation of surgically harvested bone marrow ) and is currently performed using drugs such as G-CSF . (wikidoc.org)
  • Allogeneic hematopoietic stem cell transplantation is curative but it requires a histocompatible donor and is associated with significant morbidity and mortality, so it is reserved for severe cases of PNH with aplastic anemia or transformation to leukemia. (medscape.com)
  • The patient then underwent high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (auto-PBSCT). (elsevierpure.com)
  • Thereafter, the patient received autologous peripheral blood stem cell transplantation with high-dose chemotherapy (combination of ifosphamide, carboplatin and etoposide) as pretreatment. (karger.com)
  • The most common adverse event following allogeneic hematopoietic stem cell transplantation (HSCT) is graft-versus-host disease (GVHD), which can increase morbidity and mortality in HSCT patients. (oncologynurseadvisor.com)
  • Chemotherapy, radiation, or both are initiated prior to transplantation to enable engraftment of the transplanted cells, decrease tumor size, and reduce immunoreactivity of the recipient. (oncologynurseadvisor.com)
  • 1 After transplantation, donor T cells are activated by antigen-presenting cells. (oncologynurseadvisor.com)
  • Our dedicated team of doctors, nurses, physician assistants, and transplant coordinators are specially trained in and solely devoted to blood and marrow transplantation. (uillinois.edu)
  • Genetic modification of hematopoietic stem cells with genes that inhibit replication of human immunodeficiency virus-1 (HIV-1) could lead to development of T lymphocytes and monocytic cells resistant to HIV-1 infection after transplantation. (nih.gov)
  • In addition, using iPS and iN cell technology patient-specific cells can be generated for transplantation, avoiding the need for immunosuppression and risk for rejection. (lu.se)
  • We are currently generating neurons by iPS and iN cell technology aiming to produce cortical neurons and after intracerebral transplantation or direct in vivo reprogramming of non-neuonal cells restore damaged neuronal network. (lu.se)
  • By linking together basic and clinical research, we aim to clarify cellular mechanisms of regeneration following damage to the brain and develop new therapeutic strategies to restore function in this organ (primarily in stroke and Parkinson's disease) by transplantation of stem cells or reprogrammed cells and optimization of endogenous repair mechanisms. (lu.se)
  • Our laboratory for the first time combines transplantation of stem cells, stimulation of endogenous neurogenesis and modulation of inflammatory responses in order to develop clinically effective cell replacement therapies for human neurodegenerative diseases. (lu.se)
  • Experimental treatment approaches include vaccines and nonmyeloablative allogeneic peripheral blood stem cell transplantation. (medscape.com)
  • For the purposes of this document, HSCT is defined of the CDC, the Infectious Diseases Society of America, as any transplantation of blood or marrow-derived he- and the American Society of Blood and Marrow Trans- matopoietic stem cells, regardless of transplant type plantation," which was published in the Morbidity and (allogeneic or autologous) or cell source (bone marrow, Mortality Weekly Report [1]. (cdc.gov)
  • The essence of MDS is damage of In the current work we examined All our patients were of the high-risk colony-forming units [4], but the defect haematopoietic stem cells of high-risk group and none of them was eligible of the haematopoietic stem cells is not MDS cases for apoptotic and anti-apop- for stem cell transplantation. (who.int)
  • Hematopoietic stem cell transplantation has become a major treatment option for patients with hematopoietic malignancies and immune deficiencies. (cdc.gov)
  • To the best of our knowledge, only the transmission of malarial parasites has been reported during stem cell transplantation. (cdc.gov)
  • Because of the patient's risk status, the physicians intended to perform allogeneic stem cell transplantation after induction and consolidation chemotherapy, which was scheduled to end in January 2013, and a conditioning chemotherapy regimen, which was planned to be given in March. (cdc.gov)
  • Treatment selection takes into account patient age, fitness, and whether autologous stem cell transplantation (ASCT) is planned. (medscape.com)
  • The CXCL12-3'A allele is associated with a higher mobilization yield of CD34 progenitors to the peripheral blood of healthy donors for allogeneic transplantation. (cdc.gov)
  • Donor CTLA-4 genotype influences clinical outcome after T cell-depleted allogeneic hematopoietic stem cell transplantation from HLA-identical sibling donors. (cdc.gov)
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2012 Jan 18 (1): 100-5. (cdc.gov)
  • Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse. (cdc.gov)
  • Thus, we studied the safety, efficacy, and feasibility of transfer of gene modified donor T-cells shortly after allo-HSCT in two clinical trials between 2002 and 2007 and here we compare the results to unmodified donor leukocyte infusion (DLI). (frontiersin.org)
  • The aim of these trials was to provide patients with the protection of T-cells after T-cell-depleted allo-HSCT in the matched or mismatched donor setting with an option to delete transduced T-cells, if severe aGvHD occurred within the trial period. (frontiersin.org)
  • To support evidence-based clinical guidelines on erythropoietin use for anemia in oncology, we conducted systematic reviews of controlled trials on four patient groups. (cancernetwork.com)
  • The Food and Drug Administration (FDA) has announced that breast implants filled with silicone gel may only be used in clinical trials. (stopgettingsick.com)
  • Learn more about our clinical trials and the highly specialized care teams that lead them. (cancer.gov)
  • In this review, we consider the treatment of HL in younger patients, first evaluating recent clinical trials for early-stage disease, with a special focus on which patients may still need radiotherapy (RT). (cancernetwork.com)
  • Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), has received an Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to conduct Phase 1 clinical trials with UCART123, the Company's most advanced, wholly owned TALEN® gene-edited product candidate, in patients with acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). (cellectis.com)
  • This marks the first allogeneic, "off-the-shelf" gene-edited CAR T-cell product candidate that the FDA has approved for clinical trials. (cellectis.com)
  • The FDA's approval of Cellectis' UCART123 - the first "off-the-shelf" CAR T-cell product candidate to enter clinical trials in the U.S. - is a major milestone not only for the Company but also for the medical community, global biotech and pharmaceutical industries at large," said Dr. Loan Hoang-Sayag, Cellectis Chief Medical Officer. (cellectis.com)
  • Get details on surveys, grants, and clinical trials. (primaryimmune.org)
  • This article discusses the current status of clinical trials of rituximab to treat GVHD in the pediatric population. (oncologynurseadvisor.com)
  • Our hospital is approved to be qualified for implementing stem cell clinic trials by government agencies [19]. (researchsquare.com)
  • Studies were identified through a comprehensive Medical Subject Headings (MeSH) search on the PubMed MEDLINE, Controlled Register of Clinical Trials (Cochrane CENTRAL from Wiley), Embase, and CINAHL (EBSCO) databases on February 7, 2018. (jmir.org)
  • For individuals who have acute cardiac ischemia who receive progenitor cell therapy, the evidence includes 2 randomized controlled trials (RCTs) with 200 patients, numerous small RCTs, and meta-analyses of these RCTs. (southcarolinablues.com)
  • For individuals who have refractory angina who receive progenitor cell therapy, the evidence includes phase 2 trials and a phase 3 pivotal trial. (southcarolinablues.com)
  • Additional larger trials are needed to determine whether progenitor cell therapy improves health outcomes in patients with refractory angina. (southcarolinablues.com)
  • Erik Vaessen, chief business officer at FUJIFILM Irvine Scientific, said "We are pleased to support Vitro Biopharma's clinical trials via the provision of our PRIME-XV Stem FreezIS DMSO-Free cryopreservation medium. (fujifilm.com)
  • The recent FDA authorization of these trials represents an exciting step forward in cell therapy pipelines, with the potential to remove the DMSO requirement from workflows. (fujifilm.com)
  • In recent years, clinical trials have established targeted therapy as the first-line treatment in patients with metastatic disease. (medscape.com)
  • Clinical trials are currently exploring possible future directions in treatment. (medscape.com)
  • Peripheral blood stem cells were obtained by leukapheresis after mobilization with granulocyte colony-stimulating factor. (cellsurgicalnetwork.com)
  • Quantitating the CD34+ cell population can also be useful during mobilization as well as for determining the optimal timing of apheresis sessions to make sure that enough CD34+ cells have been harvested. (bdbiosciences.com)
  • It is a very efficient inducer of hematopoietic stem cell mobilization in animal and human studies. (wikidoc.org)
  • In a small human clinical trial to evaluate the safety and efficacy of fucoidan ingestion (brown seaweed extract), 3g daily of 75% w/w oral fucoidan for 12 days increased the proportion of CD34+CXCR4+ from 45 to 90% and the serum SDF-1 levels, which could be useful in CD34+ cells homing/mobilization via SDF-1/CXCR4 axis. (wikidoc.org)
  • Positive data from the dose-escalation stage of the study, which was recently presented at the 2014 ASH (American Society of Hematology) Conference, has shown substantial mobilization of AML cancer cells from the bone marrow to the peripheral blood and robust apoptosis of these cells, as well as an excellent safety and tolerability profile. (technologynetworks.com)
  • The stem cell mobilization result was poor. (cdc.gov)
  • Before apheresis, the donor's blood count showed mild thrombocytopenia after G-CSF mobilization. (cdc.gov)
  • Association of stromal cell-derived factor-1-3'A polymorphism to higher mobilization of hematopoietic stem cells CD34+ in Tunisian population. (cdc.gov)
  • demonstrate through studies on induced pluripotent stem cell-derived cortical neurons that miR-33a is a potential therapeutic target for the treatment of SPG4-related hereditary spastic paraplegia. (portlandpress.com)
  • In conclusion, CD44v6 and ALDH1A1 are candidate stem cell markers for NPC, and the increased formation of DNA lesions by inflammation may result in the mutation of stem cells, leading to tumor development in NPC. (hindawi.com)
  • These cells are defined as tumor-initiating cells or rare cells with indefinite potential for self-renewal that drives tumorigenesis [ 15 ]. (hindawi.com)
  • [14] Another explanation of this observation is provided by a study that shows the ability of CXCL12 (and CCL2 ) producing tumors to entrain neutrophils that inhibit seeding of tumor cells in the lung. (wikidoc.org)
  • Our emerging clinical data demonstrates that these gene-modified T cells are very active in killing tumor cells initially, but they lose their ability to function within a few weeks. (ca.gov)
  • Tissue from the tumor needs to be taken to the laboratory for estrogen and progesterone tests at the time of biopsy because it may be hard to get enough cancer cells later, although newer techniques can be used on tissue that is not fresh. (stopgettingsick.com)
  • Clear cell renal cell carcinoma (ccRCC) is the seventh most frequently diagnosed tumor in adults in Europe and represents approximately 2.5% of cancer deaths. (cancerindex.org)
  • The molecular biology underlying renal cell carcinoma (RCC) development and progression has been a key milestone in the management of this type of tumor. (cancerindex.org)
  • Calebin-A induced death of malignant peripheral nerve sheath tumor cells by activation of histone acetyltransferase. (cancerindex.org)
  • In vitro , overexpression of the mdr-1 gene product, P-glycoprotein (Pgp), in tumor cells can confer high-level resistance to natural product-derived cytotoxics-anthracyclines, vinca alkaloids, epipodophyllotoxins, and taxanes. (cancer.gov)
  • Dr. Alison O'Mahony, Eurofins DiscoverX discusses the use of in vitro models of the human tumor microenvironment (TME) to qualify immuno-oncology candidates, prioritize combination strategies and predict clinical outcomes. (stemcell.com)
  • Moreover, increasing data have shown that peripheral T-cell tolerance is an essential property of the specific immune response to tumor cells. (biomedcentral.com)
  • GM-CSF is also involved in bone cancer pain development by regulating tumor-nerve interactions, remodeling of peripheral nerves and sensitization of damage-sensing (nociceptive) nerves. (iasp-pain.org)
  • Hematology/oncology is a field where clinical and basic research can be rapidly applied to improve outcomes and quality of life. (rochester.edu)
  • The HUCMSCs derived different donors have individual heterogeneity, which potentially lead to distinct therapeutic outcomes in mouse liver fibrosis, indicating we could make use of the donor-variation of MSCs to screen out guaranteed general indicators of MSCs for specific diseases in further stem cell therapy. (researchsquare.com)
  • Included studies were original articles researching the feasibility, acceptability, and clinical outcomes of telemedicine or telehealth interventions in pediatric or adult populations with malignant or nonmalignant hematological conditions. (jmir.org)
  • Limited evidence on clinical outcomes has suggested that there may be benefits from improving left ventricular ejection fraction, reducing recurrent myocardial infarction, decreasing need for further revascularization, and perhaps even decreasing mortality, although a recent, large, individual patient data meta-analysis reported no improvement in these outcomes. (southcarolinablues.com)
  • No adequately powered trial has reported benefits in clinical outcomes (e.g., mortality, adverse cardiac outcomes, exercise capacity, quality of life). (southcarolinablues.com)
  • Overall, this evidence has suggested that progenitor cell treatment may be a promising intervention, but robust data on clinical outcomes are lacking. (southcarolinablues.com)
  • High-quality RCTs, powered to detect differences in clinical outcomes, are needed to answer this question. (southcarolinablues.com)
  • However, other clinical outcomes were not reported with sufficient methodologic rigor to permit conclusions. (southcarolinablues.com)
  • The only phase 3 trial identified was terminated early and insufficiently powered to evaluate clinical outcomes. (southcarolinablues.com)
  • 8 The BD ® Stem Cell Enumeration Kit incorporates BD Trucount™ tubes to determine the absolute cell count, thereby eliminating variability associated with hematology-derived absolute counts. (bdbiosciences.com)
  • In 1998, the American Society of Hematology (ASH) and theAmerican Society of Clinical Oncology (ASCO) jointly nominated the topic'Uses of Erythropoietin in Oncology' to AHRQ for an Evidence-basedPractice Center systematic review and evidence report. (cancernetwork.com)
  • Preclinical data (presented at the European Hematology Association Conference in June 2014) show that by inhibiting the CXCR4 receptor, BL-8040 enhances the effect of FLT3 inhibition in killing FLT3-mutated leukemic cells. (technologynetworks.com)
  • Hematology & Oncology at UI Health comprises a dedicated team of doctors, nurses, social workers, and pharmacists who work to treat cancers of the blood and other blood disorders. (uillinois.edu)
  • Opportunistic infections (OIs) are defined as any in- the infusion of hematopoietic stem cells from a donor fections that occur with increased frequency or severity into a patient who has received chemotherapy, which in HSCT patients. (cdc.gov)
  • The three sources of stem cells include bone marrow, umbilical cord blood, and peripheral blood. (oncologynurseadvisor.com)
  • To compare the heterogeneities of human umbilical cord mesenchymal stem cells (HUCMSCs) derived from different donors and test their therapeutic variations in mouse liver fibrosis model. (researchsquare.com)
  • We established a Good Manufacturing Practice (GMP) grade cell facility to produce clinic-grade human umbilical cord derived MSCs (HUCMSCs) for treating premature ovarian failure (POF) and recurrent uterine adhesion [18, 20]. (researchsquare.com)
  • Vitro Biopharma is an innovative biotechnology company targeting autoimmune diseases and inflammatory disorders that are derived from culture-expanded mesenchymal stem cells ("MSCs") sourced from the Wharton's jelly of umbilical cords. (fujifilm.com)
  • peripheral blood, or placental/umbilical cord blood). (cdc.gov)
  • Although patients may present with symptoms of leukostasis (eg, respiratory distress, altered mental status) because of the presence of large numbers of lymphoblasts in the peripheral circulation, leukostasis is much less common in people with ALL than those with acute myelogenous leukemia (AML), and it occurs only in patients with the highest WBC counts (ie, several hundred thousand per μL). (medscape.com)
  • This study aims to monitor the long-term health of patients who have received a donor stem cell transplant from the NIH Clinical Center. (nih.gov)
  • Donor-T-cells were transduced with the replication-deficient retrovirus SFCMM-3, expressing HSV-TK and the truncated ΔLNGFR for selection of transduced cells. (frontiersin.org)
  • Donor chimerism was stabilized after transfusion of the transduced cells in all patients treated. (frontiersin.org)
  • Thus, prophylactic transfusion of donor T-cells has been included in many protocols, despite the increased risk for acute GvHD ( Kolb, 2008 ). (frontiersin.org)
  • Donor T-cells proliferate and inflammatory mediators are recruited. (oncologynurseadvisor.com)
  • Treatment focuses on blocking the expansion of donor T cells, as GVHD develops from the expansion of these cells. (oncologynurseadvisor.com)
  • Here, we report transmission of dengue virus to a peripheral blood stem cell recipient by a donor who had recently traveled to an area to which the virus is endemic. (cdc.gov)
  • Standard leukopheresis processing of blood from the donor was performed without problems. (cdc.gov)
  • A second apheresis or a bone marrow collection was considered, but neither was performed because the clinical condition of the donor worsened. (cdc.gov)
  • These data suggest that with appropriate pre-transplant clinical evaluation, high-dose cyclophosphamide and irradiation in the BMT preparative phase does not result in frequent, clinically relevant short-term cardiac toxicity [31]. (slideshare.net)
  • We have recently developed and tested a "second generation" EPOCH regimen (EPOCH II) to replace stem cell transplant for lymphomas requiring high-dose intensity, including poor prognosis untreated aggressive lymphomas, potentially curable relapsed lymphomas, and low-grade lymphomas. (cancer.gov)
  • This regimen is based on experimental/clinical observations that suggest infusion schedules may improve the therapeutic index of natural product-derived cytotoxics, and that high-dose alkylator therapy can overcome drug resistance in lymphoma. (cancer.gov)
  • Blood advances 2018 9 2 (17): 2254-2261. (cdc.gov)
  • Recent studies have revealed that AXL contributes to leukaemic phenotypes through activation of oncogenic signalling pathways that lead to increased cell migration and proliferation. (cancerindex.org)
  • AML is a devastating clonal hematopoietic stem cell neoplasm that is characterized by uncontrolled proliferation and accumulation of leukemic blasts in bone marrow, peripheral blood and, occasionally, in other tissues. (cellectis.com)
  • IL-2 stimulates the proliferation of B cells, augments natural killer cell activity, and inhibits granulocyte macrophage colony formation. (thermofisher.com)
  • Such immune dysfunction may be due to a disorder in thymic output function (in particular in young patients), which results in a lower level of naive T-cells in the peripheral blood available for an immune response to the proliferation and abnormal expression of the T cell receptor (TCR) repertoire. (biomedcentral.com)
  • ABSTRACT This study examined haematopoietic stem cells of 19 high-risk cases of myelodysplastic syndrome (MDS) for apoptotic and anti-apoptotic signals and cellular proliferation and correlated these with clinical and cytogenetic subtypes, particularly trisomy 8. (who.int)
  • Proliferation of microorganisms on or within body sites without detectable host immune response, cellular damage, or clinical expression. (cdc.gov)
  • Are you scheduled for a stem cell transplant with cord blood? (nih.gov)
  • This study will assess the safety and effectiveness of certain cord blood transplants. (nih.gov)
  • The study will help researchers learn the best methods for collecting, storing, and using cord blood in transplants. (nih.gov)
  • Through ongoing research, we continue to develop new and innovative treatment options using all available stem cells resources, including peripheral blood cells, cord blood, and bone marrow. (uillinois.edu)
  • 2 Evaluation of harvest adequacy requires the use of reliable progenitor cell assays and this is usually achieved by CD34 cell counting using flow cytometry. (bdbiosciences.com)
  • CD34, a transmembrane phosphoglycoprotein, is present on immature hematopoietic precursor cells and all hematopoietic colony-forming cells in bone marrow and blood, including unipotent and pluripotent progenitor cells. (bdbiosciences.com)
  • 4 CD34 expression is historically related to hematopoietic cells and it is considered as the marker of HSCs. (bdbiosciences.com)
  • 6 Fluorochrome-conjugated monoclonal antibodies directed against CD34 molecule can be used to identify CD34+ cells by flow cytometry. (bdbiosciences.com)
  • The BD ® Stem Cell Enumeration (SCE) Kit provides simultaneous enumeration of viable dual-positive CD45+/CD34+ hematopoietic stem cell populations in CD34+ absolute counts (cells/µL) as well as the percentage of the total viable leucocyte count that is CD34+ (%CD34). (bdbiosciences.com)
  • Single-platform flow cytometric absolute cell counting protocols have been shown to provide increased robustness of CD34 enumeration by limiting potential sources of imprecision. (bdbiosciences.com)
  • CD34-selection of stem cells reduces the risk of aGvHD, but also leads to increased infectious complications and relapse. (frontiersin.org)
  • We obtained bone marrow, isolated CD34(+) cells, performed in vitro transduction with a retroviral vector carrying a rev-responsive element (RRE) decoy gene, and reinfused the cells into these subjects with no evidence of adverse effects. (nih.gov)
  • Current surveillance strategies for patients with SDS and other leukemia predisposition syndromes rely on monitoring hematologic status by serial peripheral blood counts to identify worsening cytopenias and bone marrow examinations to identify morphologic changes or development of clonal chromosomal abnormalities 11 . (nature.com)
  • Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell (HSC) disease. (medscape.com)
  • For many hematopoietic malignancies, collection and infusion of CD34+ hematopoietic stem/progenitor cells following chemotherapy is critical. (bdbiosciences.com)
  • Sporadic reports of TGA occur very rarely in a variety of circumstances such as dobutamine-atropine stress echocardiography, infusion of DMSO-cryopreserved autologous peripheral blood stem cells, breathing of hyperoxic mixtures (Nitrox) in diving, intrathecal baclofen treatments, and withdrawal symptoms from a beta-blocker. (medscape.com)
  • The levels of gene-containing leukocytes in peripheral blood samples in the 1 year after gene transfer/cell infusion have been extremely low. (nih.gov)
  • Drugs that block the CXCR4 receptor appear to be capable of "mobilizing" hematopoietic stem cells into the bloodstream as peripheral blood stem cells . (wikidoc.org)
  • Plerixafor (AMD3100) is a drug, approved for routine clinical use, [7] which directly blocks the CXCR4 receptor. (wikidoc.org)
  • Expression of this receptor in cancer cells has been linked to metastasis to tissues containing a high concentration of CXCL12, such as lungs, liver and bone marrow. (wikidoc.org)
  • The patient's own white blood cells and stem cells from their blood are modified in the laboratory using genetic techniques to express a specific receptor against cancer cells. (ca.gov)
  • The specific receptor against cancer cells that will be transferred to the immune cells and stem cells is called NY-ESO-1 T cell receptor (or TCR). (ca.gov)
  • If the biopsy shows that there is cancer, it is important that certain tests (called estrogen and progesterone receptor tests) be done on the cancer cells. (stopgettingsick.com)
  • CRS generally occurs with therapies that lead to highly activated T cells, like chimeric antigen receptor T cells or in the case of bispecific T-cell engaging antibodies. (bmj.com)
  • [ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
  • UCART123 is a gene-edited T-cell investigational drug that targets CD123, an antigen expressed at the surface of leukemic cells in AML, tumoral cells in BPDCN. (cellectis.com)
  • Patients with acute lymphoblastic leukemia (ALL) present with either symptoms relating to direct infiltration of the marrow or other organs by leukemic cells, or symptoms relating to the decreased production of normal marrow elements. (medscape.com)
  • Infiltration of the marrow by massive numbers of leukemic cells frequently manifests as bone pain. (medscape.com)
  • Signs relating to organ infiltration with leukemic cells and, to a lesser degree, lymphadenopathy may be present. (medscape.com)
  • Occasionally, patients have rashes that result from infiltration of the skin with leukemic cells. (medscape.com)
  • An environment for GVHD is formed when antigen-presenting cells are activated by the patient's disease and the pretreatment destruction of cells caused by chemotherapy and radiotherapy. (oncologynurseadvisor.com)
  • Extracorporeal photopheresis inactivates antigen-presenting cells and T cells, whereas TNF antagonists decrease cellular activation and local tissue damage. (oncologynurseadvisor.com)
  • CD20 is an antigen expressed on the surface of B cells. (oncologynurseadvisor.com)
  • 4 One of the primary pathways in which T cells are activated is through antigen-presenting cells such as B cells. (oncologynurseadvisor.com)
  • Functionality of HSV-TK gene expressing T-cells was shown by loss of bcr-able gene expression as well as by control of cytomegalovirus-reactivation. (frontiersin.org)
  • This experience points to the need to have a continuous source of gene-modified cells to maintain the ability to kill cancer cells. (ca.gov)
  • In this study, we hypothesize that gene-modified stem cells will allow a sustained production of active T cells with antitumor activity. (ca.gov)
  • Since there is a delay in the appearance of the T cells that come from stem cells to get out of the bone marrow and into the blood, we will give patients both gene-modified T cells for a first wave of antitumor activity and gene-modified stem cells which will provide a bridge until the stem cells have produced more T cells. (ca.gov)
  • The purpose of the current study is to give gene-modified T cells in combination with gene-modified stem cells to reprogram the immune system to recognize and kill cancer cells that have the NY-ESO-1 protein with sustained killing activity. (ca.gov)
  • Gene modification of cells involves the transfer of foreign genetic material (DNA) into a cell, in this case the immune system cells and stem cells. (ca.gov)
  • In this study, the gene-modified immune cells will be given in combination with the gene-modified stem cells. (ca.gov)
  • To date, we have manufactured a batch of the lentiviral vector necessary to transfer the NY-ESO-1 TCR into stem cells and have demonstrated that this vector can gene-modify human stem cells. (ca.gov)
  • We have demonstrated that when mouse stem cells are gene-modified with this lentiviral vector, the stem cells take up residence in the bone marrow and produce appropriate blood cells. (ca.gov)
  • A preclinical study is also ongoing in mice to assess the safety of combining the gene-modified T cells and stem cells in mice. (ca.gov)
  • The vector includes a suicide gene which we have shown can be used to kill cells if necessary. (ca.gov)
  • This gene may be involved in several cellular functions including growth, migration, aggregation and anti-inflammation in multiple cell types. (cancerindex.org)
  • FDA Grants Cellectis IND Approval to Proceed with the Clinical Development of UCART123, the First Gene Edited Off-the-Shelf CAR T-Cell Product Candidate developed in the U.S. (cellectis.com)
  • These observations support the potential of performing gene therapy for HIV-1 using hematopoietic cells, but emphasize the need for improved gene transfer techniques. (nih.gov)
  • Working across discovery research, cell and gene therapy, reproductive medicine and cytogenetics, as well as the large-scale production of biotherapeutics and vaccines, the Company is trusted by researchers, manufacturers, and clinicians. (fujifilm.com)
  • We are currently performing clinical study to characterize the phenotype and gene expression profile of peripheral blood monocytes in patients with stroke. (lu.se)
  • We show that germline SBDS deficiency establishes a fitness constraint that drives selection of somatic clones via two distinct mechanisms with different clinical consequences. (nature.com)
  • Identification of clinical mechanisms of drug resistance. (cancer.gov)
  • The mechanisms of action of ototoxic substances may involve the entire organ, specific cells within the organ, components of specific cells, or individual biochemical pathways. (cdc.gov)
  • Mesenchymal stem cells (MSCs) have been widely tested for treating a variety of refectory medical indications such as type 1 diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis and Crohn's disease due to their multiple differentiation potentials and immunomodulation capability [1-5]. (researchsquare.com)
  • The medium is validated for use in mesenchymal stromal cells and CD34+ cells, and optimized cryopreservation protocols for peripheral blood mononuclear cells and T cells have also been published. (fujifilm.com)
  • Although many plasma cell disorders have been reported in patients with POEMS syndrome, most patients are seen with osteosclerotic myeloma or monoclonal gammopathy of unknown significance. (medscape.com)
  • The NHLBI leads or sponsors studies for patients who have heart, lung, blood, or sleep related diseases or disorders. (nih.gov)
  • Sickle cell disease is a group of inherited blood disorders that affect the hemoglobin found in red blood cells. (uillinois.edu)
  • Eleuthero might cause a pounding heart, irregular heartbeat, or high blood pressure in people who have heart disorders. (medlineplus.gov)
  • Breast cancer, a common cancer in women, is a disease in which cancer (malignant) cells are found in the tissues of the breast. (stopgettingsick.com)
  • Rituximab attaches to the CD20 surface of mature B cells and destroys both normal and malignant B cells. (oncologynurseadvisor.com)
  • Objective:To investigate the prognosis and its influencing factors of elderly patients with diffuse large B-cell lymphoma (DLBCL), and to provide references for clinical treatment.Methods:The clinical data of 152 patients with DLBCL aged over 60 years old from January 2013 to June 2017 in Shanxi Provincial Cancer Hospital were retrospectively analyzed. (bvsalud.org)
  • Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). (smw.ch)
  • ABNL-MARRO (A Basket study of Novel therapy for untreated MDS/MPN and Relapsed/Refractory Overlap Syndromes) is an international European-American cooperation providing the framework for collaborative studies to advance treatment of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and explore clinical-pathologic markers of disease severity, prognosis and treatment response. (mycancergenome.org)
  • Myeloproliferative neoplasms are a group of diseases of the bone marrow in which excess cells are produced. (uillinois.edu)
  • Renal cell carcinoma (RCC) accounts for approximately 3% of adult malignancies and 90-95% of neoplasms arising from the kidney. (medscape.com)
  • IL2 plays an important role as a growth factor, differentiation factor, and regulator of cell death. (thermofisher.com)
  • Based on their functional outcome, co-signaling molecules can be divided as co-stimulators and co-inhibitors, which positively and negatively control the priming, growth, differentiation and functional maturation of a T-cell response. (biomedcentral.com)
  • Flow cytometric enumeration of CD34+ HSCs and progenitor cells is an established method for the evaluation of bone marrow and stem cell grafts. (bdbiosciences.com)
  • Murine PD-1 mRNA expression has been shown to be correlated with activation-induced apoptosis in a mouse T-cell hybridoma cell line and murine thymocytes [ 13 ]. (biomedcentral.com)
  • Studies included in meta-analyses have reported only a handful of clinical outcome events, too few for meaningful analysis. (southcarolinablues.com)
  • This study is investigating a new method for collecting blood stem cells from donors to see if it reduces transplant complications, such as rejection, in patients who have blood diseases. (nih.gov)
  • Transduced cells were transfused either after day +60 (matched donors) or on day +42 (haploidentical donors). (frontiersin.org)
  • Exclusion of prospective blood donors based on their acknowledged risk behaviors for human immunodeficiency virus (HIV) infection began in 1983 (1). (cdc.gov)
  • In 1985, when tests for HIV antibody became available, screening prospective donors of blood, organs, and other tissues also began (2,3). (cdc.gov)
  • G-CSF is a growth factor for neutrophils (a common type of white blood cells), and may act by increasing the activity of neutrophil-derived proteases such as neutrophil elastase in the bone marrow leading to proteolytic degradation of SDF-1. (wikidoc.org)
  • Patients with ALL often have decreased neutrophil counts, regardless of whether their total white blood cell (WBC) count is low, normal, or elevated. (medscape.com)
  • The use of DMSO during cell therapies has historically been a process critical step used to maintain cell viability during cryopreservation, however DMSO toxicity has been well characterized in cells throughout the human body and can cause a wide range of undesirable side effects following stem cell therapy. (fujifilm.com)
  • 15]. The percentage of bone common of which are trisomy 8, mono- marrow blast cells for estimation of the Myelodysplastic syndrome (MDS) is somy 7 and 5q- [11]. (who.int)
  • Diagnosis of leukemia predisposition provides potential opportunities for early intervention, but data to guide precision medicine approaches to clinical surveillance are lacking. (nature.com)
  • An increase in the peripheral leukocyte count was noted 56 months after the diagnosis of MFH was made. (karger.com)
  • A strategy in the treatment of cancer by harnessing the immune system, called adoptive cell therapy, is to use an individual's own immune cells (T cells) and genetically modify them to target them to kill the cancer. (ca.gov)
  • This process will endow the recipient immune cells and descendants of the stem cells with the ability to eliminate cancer cells that express the cancer specific protein, NY-ESO-1. (ca.gov)
  • An important component is the study of immune modulation with IL-2 and peripheral blood stem cells (PBSC) on the generation of natural killer (NK) and lymphokine-activated killer cells (LAK), immune recovery, and eradication of microscopic disease posttherapy. (cancer.gov)
  • In an attempt to control infection, masses of neutrophils and other immune cells continue to gather at the site of infection, forming large groups of these cells called granulomas, hence the name of the disease. (primaryimmune.org)
  • 5 however, it has been used to treat many pediatric hematologic conditions, including chronic immune thrombocytopenic purpura, posttransplant lymphoproliferative disease, juvenile rheumatoid arthritis, and other blood dyscrasias. (oncologynurseadvisor.com)
  • The role of PD-1 and PD-L1 in T-cell immune suppression and the potential for immunotherapy via blocking PD-1 and PD-L1 in hematological malignancies are also reviewed. (biomedcentral.com)
  • METHODS: Clinical data were reviewed in 132 consecutive patients with CIDP, including typical CIDP (n = 89), multifocal acquired demyelinating sensory and motor neuropathy (MADSAM) (n = 31), distal acquired demyelinating symmetric (DADS) (n = 9) and others (n = 3). (bvsalud.org)
  • Over the past few years, MSCs researches have achieved some inspiring results and some of which moved up to clinic period from preclinical phases, resulting in the marketing approval of a few cell-based therapy products (CTPs) by different national regulatory authorities [18]. (researchsquare.com)
  • Progenitor cell therapy describes the use of multipotent cells of various cell lineages (autologous or allogeneic) for tissue repair and/or regeneration. (southcarolinablues.com)
  • Progenitor cell therapy is being investigated for the treatment of damaged myocardium resulting from acute or chronic cardiac ischemia and for refractory angina. (southcarolinablues.com)
  • For individuals who have chronic cardiac ischemia who receive progenitor cell therapy, the evidence includes a nonrandomized comparative trial and systematic reviews of smaller RCTs. (southcarolinablues.com)
  • SANTA ANA, Calif. -- FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, today announced that its PRIME-XV Stem FreezIS DMSO-Free* cryopreservation medium is to be used as an excipient in a FDA-authorized clinical trial conducted by Vitro Biopharma. (fujifilm.com)
  • 3 Following exogenous stimulation, such as chemotherapy or using growth factors such as granulocyte colony stimulating factor (G-CSF) and filgrastim, the number of HSCs in the peripheral blood increases, either becoming on par or even exceeding the number in the bone marrow. (bdbiosciences.com)
  • BD Biosciences offers flow cytometers and assays for the enumeration of CD34+ cells. (bdbiosciences.com)
  • In vitro assays have also been performed to assess whether the lentiviral vector could potentially transform cells. (ca.gov)
  • Liquid biopsy for invasive mold infections in hematopoietic cell transplant recipients with pneumonia through next-generation sequencing of microbial cell-free DNA in plasma. (stanford.edu)
  • Hopefully, following the recommendations made in the guidelines will reduce morbidity and mortality from opportunistic infections in hematopoietic stem cell transplant recipients. (cdc.gov)
  • The problematic nature of VGS species assignment also extends to16S rRNA sequencing, the most widely used genetic tool for species identification in clinical and research settings ( 9 , 10 ). (cdc.gov)
  • Moreover, several studies have shown that cancer cells have genetic instability, epigenetic changes, and an accumulation of mutations, suggesting that cancer is a genetic disease [ 16 ]. (hindawi.com)
  • These results mechanistically link leukemia predisposition to germline genetic constraints on cellular fitness, and provide a rational framework for clinical surveillance strategies. (nature.com)